Foreword.
作者信息
Hyman D M, Ladanyi M
机构信息
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Ann Oncol. 2019 Nov;30 Suppl 8(Suppl 8):viii1-viii2. doi: 10.1093/annonc/mdz409. Epub 2019 Dec 24.
Abstract
摘要
相似文献
1
Foreword.前言。
Ann Oncol. 2019 Nov;30 Suppl 8(Suppl 8):viii1-viii2. doi: 10.1093/annonc/mdz409. Epub 2019 Dec 24.
2
On the right TRK: from oncogene discovery to cancer therapeutics.右侧TRK：从癌基因发现到癌症治疗
Ann Oncol. 2019 Nov;30 Suppl 8(Suppl 8):viii3-viii4. doi: 10.1093/annonc/mdz290. Epub 2019 Dec 24.
3
TRK inhibitors in TRK fusion-positive cancers.TRK 抑制剂在 TRK 融合阳性癌症中的应用。
Ann Oncol. 2019 Nov;30 Suppl 8:viii23-viii30. doi: 10.1093/annonc/mdz282. Epub 2019 Dec 24.
4
Larotrectinib in NTRK-Rearranged Solid Tumors.拉罗替尼治疗NTRK重排实体瘤
Biochemistry. 2019 Mar 26;58(12):1555-1557. doi: 10.1021/acs.biochem.9b00126. Epub 2019 Mar 13.
5
Loxo TRK inhibitor data wows oncologists.Loxo TRK抑制剂数据令肿瘤学家惊叹。
Nat Biotechnol. 2017 Aug 8;35(8):694-695. doi: 10.1038/nbt0817-694.
6
Improving outcomes in pediatric NTRK gene fusion-positive solid tumors: importance of genomic testing and targeted therapy with the TRK inhibitor larotrectinib.改善儿童NTRK基因融合阳性实体瘤的治疗效果：基因检测及使用TRK抑制剂拉罗替尼进行靶向治疗的重要性
Clin Adv Hematol Oncol. 2024 May;22 Suppl 3(4):1-11.
7
Rearranged-in-transfection inhibitors: emerging agnostic targeted therapies for solid tumors.转染重排抑制剂：实体瘤新兴的非特异性靶向治疗方法
Pharmacogenomics. 2021 Apr;22(5):247-250. doi: 10.2217/pgs-2021-0002. Epub 2021 Mar 23.
8
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.一种下一代 TRK 激酶抑制剂克服了 TRK 融合阳性实体瘤患者对先前 TRK 激酶抑制的获得性耐药。
Cancer Discov. 2017 Sep;7(9):963-972. doi: 10.1158/2159-8290.CD-17-0507. Epub 2017 Jun 3.
9
Fibroblastic orbital tumour with NTRK1 fusion transcript: when TRK inhibitors rescue surgery.
Can J Ophthalmol. 2024 Aug;59(4):e407-e409. doi: 10.1016/j.jcjo.2023.11.008. Epub 2023 Dec 11.
10
[Back from ASCO 2019: Advances on NTRK inhibitors in childhood tumors].
Bull Cancer. 2019 Jul-Aug;106(7-8):615-616. doi: 10.1016/j.bulcan.2019.06.001. Epub 2019 Jul 1.
引用本文的文献
1
Therapeutic developments in pancreatic cancer.胰腺癌的治疗进展。
Nat Rev Gastroenterol Hepatol. 2024 Jan;21(1):7-24. doi: 10.1038/s41575-023-00840-w. Epub 2023 Oct 5.
本文引用的文献
1
Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.婴儿复发性、化疗耐药性婴儿纤维肉瘤携带特征性 ETV6-NTRK3 基因融合，对 TRK 抑制剂拉罗替尼快速、完全和持续的肿瘤反应。
Ann Oncol. 2019 Nov;30 Suppl 8:viii31-viii35. doi: 10.1093/annonc/mdz382. Epub 2019 Dec 24.
2
On the right TRK: from oncogene discovery to cancer therapeutics.右侧TRK：从癌基因发现到癌症治疗
Ann Oncol. 2019 Nov;30 Suppl 8(Suppl 8):viii3-viii4. doi: 10.1093/annonc/mdz290. Epub 2019 Dec 24.
3
TRK inhibitors in TRK fusion-positive cancers.TRK 抑制剂在 TRK 融合阳性癌症中的应用。
Ann Oncol. 2019 Nov;30 Suppl 8:viii23-viii30. doi: 10.1093/annonc/mdz282. Epub 2019 Dec 24.
4
Identifying patients with NTRK fusion cancer.识别具有 NTRK 融合癌症的患者。
Ann Oncol. 2019 Nov;30 Suppl 8:viii16-viii22. doi: 10.1093/annonc/mdz384. Epub 2019 Dec 24.
5
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer.原肌球蛋白受体激酶（TRK）生物学和 NTRK 基因融合在癌症中的作用。
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii5-viii15. doi: 10.1093/annonc/mdz383.
6
Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion.患者患有胰腺腺癌，存在 NTRK 基因融合，对 TRK 抑制有反应。
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii36-viii40. doi: 10.1093/annonc/mdz385. Epub 2019 Dec 24.
Zotero 插件